By vgreene, 28 October, 2021 Study considerations non randomized weighted propensity score model treatment bias HCQ pts were generally sicker missing data and inaccuracies in EHR
By vgreene, 28 October, 2021 KEY FINDINGS HCQ not assoc w change in composite endpoint intubation or death
By vgreene, 28 October, 2021 Observational Study of Hydroxychloroquine in Hospitalized Patients With COVID 19
By vgreene, 28 October, 2021 Overall 28 day mortality 12 no significant difference in reduced mortality w death rate ratio vs control RDV RR 0 95 95 CI 0 81 1 11 HCQ RR 1 19 95 CI 0 89 1 59 LPV r RR 1 00 95 CI 0 79 1 25 and IFN RR 1 16 95 CI 0 96 1 39 no significant difference in ven
By vgreene, 28 October, 2021 Multinational randomized study 11 266 hospitalized pts 10 ventilated w COVID 19 received either RDV n 2 750 HCQ n 954 LPV r n 1 411 IFN beta 1a LPV r n 651 IFN beta 1a n 1 412 or SOC n 4 088 pts could receive other therapies incl CS immunomodulators and o
By vgreene, 28 October, 2021 Study considerations not peer reviewed randomized interim analysis significant proportion of pts received other potential treatments for COVID varied by tx arm sx duration not reported excluded peds pts
By vgreene, 28 October, 2021 KEY FINDINGS HCQ had little no effect on mortality vent initiation or length of stay
By vgreene, 28 October, 2021 Repurposed Antiviral Drugs for Covid 19 Interim WHO Solidarity Trial Results
